| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 49 | 2022 | 561 | 10.920 |
Why?
|
| Dinoprostone | 39 | 2022 | 110 | 9.060 |
Why?
|
| Cyclooxygenase 2 | 46 | 2022 | 160 | 4.900 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 33 | 2015 | 73 | 4.450 |
Why?
|
| Adenoma | 12 | 2022 | 132 | 3.630 |
Why?
|
| Isoenzymes | 22 | 2005 | 308 | 3.210 |
Why?
|
| Neoplasms | 21 | 2022 | 1667 | 3.090 |
Why?
|
| Cyclooxygenase Inhibitors | 20 | 2009 | 73 | 2.730 |
Why?
|
| Inflammation Mediators | 8 | 2021 | 244 | 2.720 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 22 | 2022 | 240 | 2.710 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 21 | 2021 | 46 | 2.490 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2022 | 40 | 2.440 |
Why?
|
| Signal Transduction | 34 | 2022 | 2689 | 2.070 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 8 | 2014 | 66 | 2.030 |
Why?
|
| Prostaglandins | 11 | 2018 | 65 | 1.980 |
Why?
|
| Tumor Microenvironment | 7 | 2022 | 213 | 1.830 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2016 | 756 | 1.800 |
Why?
|
| Animals | 86 | 2022 | 20881 | 1.750 |
Why?
|
| Transcription Factors | 13 | 2010 | 753 | 1.750 |
Why?
|
| Inflammation | 11 | 2022 | 1030 | 1.720 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2020 | 235 | 1.700 |
Why?
|
| Early Detection of Cancer | 3 | 2022 | 454 | 1.630 |
Why?
|
| Tumor Escape | 4 | 2021 | 37 | 1.600 |
Why?
|
| Sulfonamides | 7 | 2014 | 141 | 1.600 |
Why?
|
| Intestinal Neoplasms | 6 | 2012 | 30 | 1.550 |
Why?
|
| Colitis | 4 | 2014 | 156 | 1.530 |
Why?
|
| Humans | 120 | 2022 | 68618 | 1.450 |
Why?
|
| Hydroxyprostaglandin Dehydrogenases | 6 | 2012 | 8 | 1.420 |
Why?
|
| Periodicals as Topic | 8 | 2022 | 158 | 1.400 |
Why?
|
| Eicosanoids | 5 | 2011 | 16 | 1.370 |
Why?
|
| Neoplasm Metastasis | 7 | 2019 | 306 | 1.340 |
Why?
|
| Intestinal Mucosa | 13 | 2014 | 219 | 1.330 |
Why?
|
| Colonic Neoplasms | 8 | 2012 | 299 | 1.320 |
Why?
|
| Cell Movement | 8 | 2015 | 630 | 1.290 |
Why?
|
| PPAR delta | 6 | 2019 | 14 | 1.250 |
Why?
|
| Mice | 41 | 2022 | 8474 | 1.230 |
Why?
|
| Pyrazoles | 8 | 2009 | 190 | 1.200 |
Why?
|
| Anticarcinogenic Agents | 5 | 2006 | 52 | 1.150 |
Why?
|
| Cell Line, Tumor | 22 | 2016 | 1851 | 1.110 |
Why?
|
| Carcinogenesis | 2 | 2020 | 124 | 1.100 |
Why?
|
| Epithelial Cells | 10 | 2021 | 431 | 1.090 |
Why?
|
| Carcinoma | 3 | 2015 | 215 | 1.080 |
Why?
|
| ErbB Receptors | 9 | 2007 | 239 | 1.000 |
Why?
|
| Intestines | 7 | 2020 | 114 | 0.940 |
Why?
|
| Membrane Proteins | 23 | 2005 | 617 | 0.890 |
Why?
|
| Neovascularization, Pathologic | 8 | 2009 | 183 | 0.890 |
Why?
|
| Antineoplastic Agents | 8 | 2021 | 1070 | 0.840 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2021 | 14 | 0.840 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 334 | 0.840 |
Why?
|
| Aromatase | 2 | 2012 | 8 | 0.840 |
Why?
|
| Thiazolidinediones | 3 | 2012 | 77 | 0.820 |
Why?
|
| Cyclooxygenase 1 | 9 | 2019 | 29 | 0.810 |
Why?
|
| Famous Persons | 1 | 2022 | 15 | 0.800 |
Why?
|
| Neoplastic Stem Cells | 3 | 2019 | 84 | 0.780 |
Why?
|
| Dietary Fats | 2 | 2019 | 103 | 0.770 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 30 | 0.770 |
Why?
|
| Chemokine CXCL1 | 3 | 2017 | 21 | 0.770 |
Why?
|
| Tumor Cells, Cultured | 12 | 2019 | 852 | 0.770 |
Why?
|
| ras Proteins | 4 | 2006 | 102 | 0.750 |
Why?
|
| Hypoxia | 2 | 2013 | 169 | 0.740 |
Why?
|
| Cell Proliferation | 8 | 2015 | 1174 | 0.720 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 307 | 0.700 |
Why?
|
| Breast Neoplasms | 4 | 2013 | 1536 | 0.670 |
Why?
|
| Receptors, Interleukin-8B | 3 | 2014 | 9 | 0.650 |
Why?
|
| Phosphoproteins | 2 | 2010 | 202 | 0.640 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2010 | 214 | 0.640 |
Why?
|
| Repressor Proteins | 4 | 2008 | 183 | 0.620 |
Why?
|
| Receptors, Prostaglandin E | 3 | 2007 | 8 | 0.620 |
Why?
|
| Zebrafish | 4 | 2010 | 187 | 0.620 |
Why?
|
| Gastrula | 3 | 2010 | 17 | 0.610 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 231 | 0.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2012 | 468 | 0.610 |
Why?
|
| Obesity | 3 | 2018 | 1076 | 0.600 |
Why?
|
| Promoter Regions, Genetic | 8 | 2019 | 615 | 0.590 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.590 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.590 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 5 | 2022 | 12 | 0.580 |
Why?
|
| MicroRNAs | 3 | 2019 | 447 | 0.580 |
Why?
|
| Wnt Proteins | 3 | 2006 | 57 | 0.570 |
Why?
|
| Thiazoles | 6 | 2019 | 95 | 0.570 |
Why?
|
| Early Growth Response Protein 1 | 2 | 2016 | 42 | 0.570 |
Why?
|
| Pandemics | 1 | 2020 | 352 | 0.560 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2013 | 300 | 0.560 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 25 | 0.550 |
Why?
|
| HCT116 Cells | 5 | 2019 | 63 | 0.550 |
Why?
|
| Disease Progression | 9 | 2013 | 1038 | 0.550 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2006 | 22 | 0.540 |
Why?
|
| Lung Neoplasms | 7 | 2013 | 1173 | 0.540 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2006 | 219 | 0.540 |
Why?
|
| Arrestins | 2 | 2006 | 92 | 0.510 |
Why?
|
| Colon | 3 | 2014 | 168 | 0.510 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 597 | 0.510 |
Why?
|
| Genes, APC | 6 | 2015 | 15 | 0.510 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2006 | 146 | 0.510 |
Why?
|
| Cell Hypoxia | 2 | 2013 | 92 | 0.500 |
Why?
|
| Biomarkers, Tumor | 3 | 2015 | 508 | 0.490 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2013 | 71 | 0.470 |
Why?
|
| Furans | 1 | 2014 | 27 | 0.470 |
Why?
|
| Aspirin | 4 | 2007 | 295 | 0.470 |
Why?
|
| Cell Survival | 8 | 2016 | 901 | 0.470 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 2 | 2011 | 3 | 0.460 |
Why?
|
| Intestinal Polyps | 4 | 2008 | 15 | 0.460 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2015 | 250 | 0.460 |
Why?
|
| Drug Delivery Systems | 3 | 2005 | 236 | 0.460 |
Why?
|
| Mice, Knockout | 7 | 2014 | 1692 | 0.450 |
Why?
|
| Apoptosis | 8 | 2008 | 1641 | 0.440 |
Why?
|
| Myeloid Cells | 1 | 2013 | 57 | 0.440 |
Why?
|
| Mice, Inbred NOD | 3 | 2019 | 138 | 0.430 |
Why?
|
| DNA Methylation | 2 | 2012 | 193 | 0.430 |
Why?
|
| Postmenopause | 1 | 2013 | 93 | 0.430 |
Why?
|
| BRCA1 Protein | 1 | 2012 | 30 | 0.420 |
Why?
|
| PPAR gamma | 2 | 2012 | 95 | 0.420 |
Why?
|
| Fatty Acid Synthases | 1 | 2012 | 6 | 0.410 |
Why?
|
| Mammary Glands, Human | 1 | 2012 | 33 | 0.400 |
Why?
|
| Mice, Inbred C57BL | 8 | 2021 | 2791 | 0.400 |
Why?
|
| Neoplasms, Experimental | 2 | 2011 | 118 | 0.400 |
Why?
|
| Angiopoietins | 1 | 2011 | 4 | 0.400 |
Why?
|
| Melanoma | 1 | 2015 | 335 | 0.400 |
Why?
|
| Research | 2 | 2003 | 214 | 0.390 |
Why?
|
| Up-Regulation | 5 | 2019 | 682 | 0.390 |
Why?
|
| Primary Prevention | 2 | 2018 | 115 | 0.380 |
Why?
|
| Heterografts | 3 | 2017 | 70 | 0.380 |
Why?
|
| HT29 Cells | 3 | 2021 | 42 | 0.380 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2022 | 223 | 0.370 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2010 | 7 | 0.370 |
Why?
|
| Rats | 15 | 2014 | 5300 | 0.370 |
Why?
|
| Fatty Acids | 1 | 2011 | 222 | 0.360 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2008 | 68 | 0.360 |
Why?
|
| Celecoxib | 5 | 2009 | 22 | 0.360 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 304 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2022 | 331 | 0.350 |
Why?
|
| Transfection | 6 | 2015 | 782 | 0.350 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 778 | 0.350 |
Why?
|
| Transcriptional Activation | 3 | 2006 | 226 | 0.340 |
Why?
|
| Dextran Sulfate | 3 | 2014 | 88 | 0.340 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 362 | 0.340 |
Why?
|
| Mice, SCID | 3 | 2017 | 238 | 0.330 |
Why?
|
| Blotting, Western | 7 | 2013 | 954 | 0.320 |
Why?
|
| Enzyme Activation | 6 | 2007 | 791 | 0.320 |
Why?
|
| Models, Biological | 5 | 2018 | 981 | 0.320 |
Why?
|
| Gene Knockdown Techniques | 2 | 2021 | 196 | 0.320 |
Why?
|
| Body Mass Index | 1 | 2012 | 867 | 0.310 |
Why?
|
| Ovarian Neoplasms | 3 | 2007 | 267 | 0.310 |
Why?
|
| Clinical Trials as Topic | 8 | 2009 | 848 | 0.310 |
Why?
|
| Precision Medicine | 1 | 2009 | 111 | 0.310 |
Why?
|
| Mice, Nude | 6 | 2013 | 294 | 0.300 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 99 | 0.300 |
Why?
|
| Carrier Proteins | 2 | 2008 | 597 | 0.300 |
Why?
|
| Chronic Disease | 4 | 2015 | 1330 | 0.300 |
Why?
|
| Enzyme Inhibitors | 4 | 2008 | 659 | 0.290 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 475 | 0.290 |
Why?
|
| Quinazolines | 1 | 2007 | 70 | 0.290 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2007 | 150 | 0.290 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2007 | 147 | 0.290 |
Why?
|
| Mice, Transgenic | 7 | 2015 | 1033 | 0.290 |
Why?
|
| Male | 20 | 2019 | 37321 | 0.280 |
Why?
|
| Gastrointestinal Diseases | 2 | 2004 | 107 | 0.280 |
Why?
|
| Endothelial Growth Factors | 2 | 2003 | 25 | 0.270 |
Why?
|
| Immune Tolerance | 2 | 2018 | 114 | 0.270 |
Why?
|
| Prognosis | 4 | 2016 | 2093 | 0.270 |
Why?
|
| Lymphokines | 2 | 2003 | 49 | 0.270 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 16 | 0.270 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 700 | 0.270 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2019 | 38 | 0.270 |
Why?
|
| Cell Nucleus | 2 | 2006 | 305 | 0.270 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 95 | 0.270 |
Why?
|
| Protein Kinases | 1 | 2006 | 122 | 0.270 |
Why?
|
| Genes, ras | 2 | 2005 | 46 | 0.270 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2013 | 710 | 0.260 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 266 | 0.260 |
Why?
|
| Cell Line | 8 | 2006 | 1752 | 0.260 |
Why?
|
| Macrophages | 3 | 2018 | 647 | 0.260 |
Why?
|
| RNA, Messenger | 6 | 2011 | 1664 | 0.260 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 498 | 0.260 |
Why?
|
| Tumor Burden | 3 | 2015 | 132 | 0.250 |
Why?
|
| Arachidonate 15-Lipoxygenase | 2 | 2005 | 2 | 0.250 |
Why?
|
| Embryonic Development | 1 | 2005 | 100 | 0.250 |
Why?
|
| RNA Interference | 3 | 2015 | 266 | 0.250 |
Why?
|
| CD55 Antigens | 1 | 2004 | 13 | 0.250 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2006 | 167 | 0.250 |
Why?
|
| Blood Vessels | 1 | 2005 | 102 | 0.240 |
Why?
|
| Gastrointestinal Tract | 1 | 2005 | 63 | 0.240 |
Why?
|
| Esophageal Neoplasms | 2 | 2003 | 150 | 0.240 |
Why?
|
| Azoxymethane | 2 | 2014 | 28 | 0.230 |
Why?
|
| Leukotriene A4 | 1 | 2003 | 2 | 0.230 |
Why?
|
| Epoxide Hydrolases | 1 | 2003 | 8 | 0.230 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 142 | 0.230 |
Why?
|
| Mice, Mutant Strains | 2 | 2019 | 166 | 0.230 |
Why?
|
| Blotting, Northern | 6 | 2005 | 189 | 0.220 |
Why?
|
| Leucine | 1 | 2003 | 41 | 0.220 |
Why?
|
| Transforming Growth Factor beta | 2 | 2003 | 384 | 0.220 |
Why?
|
| Religious Missions | 1 | 2022 | 1 | 0.220 |
Why?
|
| Female | 20 | 2013 | 38074 | 0.220 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2003 | 82 | 0.220 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2004 | 282 | 0.210 |
Why?
|
| Gene Expression Regulation | 6 | 2006 | 1293 | 0.210 |
Why?
|
| Arachidonic Acid | 4 | 2007 | 86 | 0.210 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 532 | 0.210 |
Why?
|
| Cell Division | 4 | 2005 | 541 | 0.210 |
Why?
|
| Public Health | 2 | 2021 | 201 | 0.210 |
Why?
|
| Biomedical Research | 2 | 2018 | 310 | 0.210 |
Why?
|
| Gastroenterology | 1 | 2003 | 98 | 0.210 |
Why?
|
| Colonoscopy | 1 | 2003 | 156 | 0.200 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 230 | 0.200 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2021 | 9 | 0.200 |
Why?
|
| Transplantation, Heterologous | 3 | 2013 | 122 | 0.200 |
Why?
|
| Barrett Esophagus | 1 | 2002 | 57 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2007 | 320 | 0.200 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 940 | 0.200 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 87 | 0.190 |
Why?
|
| Snail Family Transcription Factors | 4 | 2010 | 31 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 91 | 0.190 |
Why?
|
| Health Promotion | 1 | 2004 | 407 | 0.180 |
Why?
|
| Cells, Cultured | 7 | 2013 | 2673 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2004 | 411 | 0.180 |
Why?
|
| HEK293 Cells | 1 | 2021 | 326 | 0.180 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2012 | 61 | 0.180 |
Why?
|
| Mass Screening | 2 | 2021 | 843 | 0.170 |
Why?
|
| United States | 5 | 2022 | 7367 | 0.170 |
Why?
|
| Physicians | 1 | 2003 | 324 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2021 | 215 | 0.170 |
Why?
|
| Nanog Homeobox Protein | 1 | 2019 | 6 | 0.170 |
Why?
|
| Disease Models, Animal | 4 | 2014 | 2550 | 0.170 |
Why?
|
| Ligands | 4 | 2008 | 317 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2010 | 59 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 4 | 2004 | 369 | 0.170 |
Why?
|
| DNA Primers | 4 | 2010 | 302 | 0.170 |
Why?
|
| Immunohistochemistry | 5 | 2013 | 1174 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.160 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 81 | 0.160 |
Why?
|
| RNA, Long Noncoding | 1 | 2019 | 54 | 0.160 |
Why?
|
| Base Sequence | 4 | 2011 | 1015 | 0.150 |
Why?
|
| Carcinogens | 1 | 2018 | 86 | 0.150 |
Why?
|
| Immunoprecipitation | 2 | 2010 | 132 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 65 | 0.150 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 94 | 0.150 |
Why?
|
| In Situ Hybridization | 4 | 2010 | 201 | 0.150 |
Why?
|
| Stem Cell Niche | 1 | 2017 | 7 | 0.150 |
Why?
|
| Risk Factors | 3 | 2015 | 5731 | 0.150 |
Why?
|
| Epoprostenol | 4 | 2007 | 71 | 0.150 |
Why?
|
| Phosphorylation | 3 | 2006 | 1200 | 0.140 |
Why?
|
| Risk | 2 | 2010 | 563 | 0.140 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2007 | 328 | 0.140 |
Why?
|
| beta-Arrestins | 2 | 2006 | 80 | 0.140 |
Why?
|
| Down-Regulation | 2 | 2008 | 447 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2015 | 7 | 0.130 |
Why?
|
| Fibroblasts | 1 | 2020 | 902 | 0.130 |
Why?
|
| Adenomatous Polyposis Coli | 3 | 2004 | 26 | 0.130 |
Why?
|
| Protein Transport | 2 | 2006 | 280 | 0.130 |
Why?
|
| Caco-2 Cells | 2 | 2006 | 37 | 0.130 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2007 | 62 | 0.130 |
Why?
|
| NF-kappa B | 2 | 2015 | 432 | 0.120 |
Why?
|
| Time Factors | 5 | 2007 | 4655 | 0.120 |
Why?
|
| Prostaglandin-E Synthases | 2 | 2006 | 6 | 0.120 |
Why?
|
| Awards and Prizes | 1 | 2015 | 27 | 0.120 |
Why?
|
| Intramolecular Oxidoreductases | 2 | 2006 | 10 | 0.120 |
Why?
|
| Cell Growth Processes | 3 | 2010 | 40 | 0.120 |
Why?
|
| Chemoprevention | 2 | 2005 | 26 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2015 | 110 | 0.120 |
Why?
|
| Receptors, Prostaglandin | 2 | 2005 | 74 | 0.120 |
Why?
|
| Gene Expression | 3 | 2013 | 770 | 0.120 |
Why?
|
| Societies, Medical | 2 | 2018 | 403 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 195 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 492 | 0.110 |
Why?
|
| Chemotaxis | 1 | 2013 | 38 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2013 | 66 | 0.110 |
Why?
|
| Cell Communication | 1 | 2014 | 116 | 0.110 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2013 | 3 | 0.110 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2013 | 9 | 0.110 |
Why?
|
| Alprostadil | 1 | 2013 | 20 | 0.110 |
Why?
|
| Protein Binding | 1 | 2016 | 1027 | 0.110 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 100 | 0.110 |
Why?
|
| Monocytes | 1 | 2014 | 210 | 0.110 |
Why?
|
| Metabolomics | 1 | 2013 | 28 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2004 | 97 | 0.110 |
Why?
|
| Colonic Polyps | 2 | 2003 | 63 | 0.110 |
Why?
|
| Arachidonic Acids | 3 | 2007 | 97 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2004 | 1745 | 0.100 |
Why?
|
| Research Report | 1 | 2012 | 35 | 0.100 |
Why?
|
| Morbidity | 1 | 2012 | 130 | 0.100 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2012 | 5 | 0.100 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 8 | 0.100 |
Why?
|
| Luciferases | 2 | 2010 | 105 | 0.100 |
Why?
|
| Global Health | 1 | 2012 | 136 | 0.100 |
Why?
|
| Receptors, Prostaglandin E, EP1 Subtype | 1 | 2011 | 1 | 0.100 |
Why?
|
| Cytidine Deaminase | 1 | 2011 | 17 | 0.100 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2011 | 5 | 0.100 |
Why?
|
| STAT1 Transcription Factor | 1 | 2011 | 35 | 0.100 |
Why?
|
| Immediate-Early Proteins | 1 | 1991 | 63 | 0.100 |
Why?
|
| Food | 1 | 1991 | 52 | 0.100 |
Why?
|
| DNA Repair | 1 | 2012 | 127 | 0.090 |
Why?
|
| Child | 1 | 2021 | 6405 | 0.090 |
Why?
|
| Prostaglandins G | 1 | 2010 | 2 | 0.090 |
Why?
|
| Neoplastic Processes | 1 | 2010 | 2 | 0.090 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2010 | 43 | 0.090 |
Why?
|
| Pregnancy, Animal | 2 | 2007 | 27 | 0.090 |
Why?
|
| Aurora Kinase A | 1 | 2010 | 2 | 0.090 |
Why?
|
| Aurora Kinases | 1 | 2010 | 3 | 0.090 |
Why?
|
| Epigenesis, Genetic | 2 | 2008 | 163 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2015 | 2007 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 282 | 0.090 |
Why?
|
| Rats, Inbred Strains | 2 | 2005 | 532 | 0.090 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 567 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2011 | 222 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2010 | 113 | 0.080 |
Why?
|
| Zebrafish Proteins | 2 | 2010 | 100 | 0.080 |
Why?
|
| Histone Deacetylase 2 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Chemokines | 1 | 2009 | 119 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2009 | 127 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2011 | 322 | 0.080 |
Why?
|
| PPAR-beta | 1 | 2008 | 1 | 0.080 |
Why?
|
| Organ Specificity | 2 | 2013 | 167 | 0.080 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2008 | 40 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2003 | 1034 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2010 | 312 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2009 | 248 | 0.080 |
Why?
|
| Organic Anion Transporters | 1 | 2008 | 5 | 0.080 |
Why?
|
| Cardiovascular System | 1 | 2009 | 85 | 0.080 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2008 | 24 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 2 | 2006 | 261 | 0.080 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2007 | 12 | 0.080 |
Why?
|
| Transcription, Genetic | 3 | 2007 | 562 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 114 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 116 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2008 | 137 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 148 | 0.070 |
Why?
|
| Camptothecin | 1 | 2007 | 39 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2006 | 525 | 0.070 |
Why?
|
| Lipoxygenase | 1 | 2007 | 13 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2007 | 89 | 0.070 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 59 | 0.070 |
Why?
|
| Chromatography | 1 | 2007 | 47 | 0.070 |
Why?
|
| Radioimmunoassay | 1 | 2007 | 164 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 82 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 196 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2007 | 120 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2003 | 30 | 0.070 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2006 | 30 | 0.070 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2007 | 139 | 0.070 |
Why?
|
| Solvents | 1 | 2007 | 109 | 0.070 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2006 | 43 | 0.070 |
Why?
|
| Densitometry | 1 | 2006 | 15 | 0.070 |
Why?
|
| beta-Arrestin 1 | 1 | 2006 | 22 | 0.070 |
Why?
|
| Axin Protein | 1 | 2006 | 6 | 0.070 |
Why?
|
| Societies, Scientific | 2 | 2018 | 18 | 0.070 |
Why?
|
| Phosphotyrosine | 1 | 2006 | 41 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2006 | 17 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2006 | 57 | 0.070 |
Why?
|
| Atrophy | 1 | 2006 | 112 | 0.070 |
Why?
|
| Laminin | 1 | 2006 | 62 | 0.070 |
Why?
|
| Prostatectomy | 1 | 2006 | 87 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2006 | 64 | 0.070 |
Why?
|
| Isoprostanes | 1 | 2005 | 3 | 0.070 |
Why?
|
| Decision Making | 1 | 2009 | 410 | 0.070 |
Why?
|
| Cytosol | 1 | 2006 | 123 | 0.070 |
Why?
|
| Cyclopentanes | 1 | 2005 | 15 | 0.070 |
Why?
|
| DNA, Complementary | 2 | 2002 | 251 | 0.060 |
Why?
|
| beta Catenin | 1 | 2006 | 73 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2006 | 138 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2006 | 103 | 0.060 |
Why?
|
| src-Family Kinases | 1 | 2006 | 91 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2006 | 91 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 48 | 0.060 |
Why?
|
| Safety | 1 | 2006 | 145 | 0.060 |
Why?
|
| Prostate | 1 | 2006 | 116 | 0.060 |
Why?
|
| Microinjections | 1 | 2005 | 130 | 0.060 |
Why?
|
| Phospholipase D | 1 | 2005 | 13 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2006 | 304 | 0.060 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2004 | 7 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 245 | 0.060 |
Why?
|
| Ovum Transport | 1 | 2004 | 1 | 0.060 |
Why?
|
| Ibuprofen | 1 | 2004 | 30 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2004 | 41 | 0.060 |
Why?
|
| Chromones | 1 | 2004 | 33 | 0.060 |
Why?
|
| Models, Animal | 1 | 2005 | 252 | 0.060 |
Why?
|
| Reoviridae | 1 | 2004 | 14 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 247 | 0.060 |
Why?
|
| Isoproterenol | 1 | 2004 | 163 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2004 | 89 | 0.060 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2004 | 92 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2005 | 87 | 0.060 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2004 | 30 | 0.060 |
Why?
|
| Sulindac | 1 | 2004 | 4 | 0.060 |
Why?
|
| Morpholines | 1 | 2004 | 79 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 93 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 53 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2005 | 489 | 0.060 |
Why?
|
| Mesoderm | 1 | 2005 | 231 | 0.060 |
Why?
|
| DNA Damage | 1 | 2005 | 190 | 0.060 |
Why?
|
| Masoprocol | 1 | 2004 | 3 | 0.060 |
Why?
|
| Stearic Acids | 1 | 2004 | 6 | 0.060 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2004 | 45 | 0.060 |
Why?
|
| Leukotrienes | 1 | 2004 | 13 | 0.060 |
Why?
|
| Lipid Peroxides | 1 | 2004 | 19 | 0.060 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2004 | 9 | 0.060 |
Why?
|
| Butyrates | 1 | 2004 | 14 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 371 | 0.060 |
Why?
|
| Acetaminophen | 1 | 2004 | 111 | 0.060 |
Why?
|
| Norepinephrine | 1 | 2004 | 276 | 0.060 |
Why?
|
| Virus Replication | 1 | 2004 | 104 | 0.060 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2003 | 14 | 0.060 |
Why?
|
| Lipocalins | 1 | 2003 | 7 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 446 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 234 | 0.060 |
Why?
|
| Thromboxane-A Synthase | 1 | 2003 | 24 | 0.060 |
Why?
|
| Sheep | 1 | 2003 | 128 | 0.050 |
Why?
|
| Keratin-20 | 1 | 2002 | 3 | 0.050 |
Why?
|
| Intermediate Filament Proteins | 1 | 2002 | 12 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 357 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 649 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2002 | 51 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 88 | 0.050 |
Why?
|
| Forecasting | 1 | 2004 | 277 | 0.050 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2003 | 67 | 0.050 |
Why?
|
| Transgenes | 1 | 2002 | 92 | 0.050 |
Why?
|
| Cyclins | 1 | 2002 | 50 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 137 | 0.050 |
Why?
|
| COS Cells | 1 | 2002 | 155 | 0.050 |
Why?
|
| Collagen | 1 | 2006 | 636 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 204 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2004 | 185 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2004 | 714 | 0.050 |
Why?
|
| Ovary | 1 | 2002 | 99 | 0.050 |
Why?
|
| Cell Adhesion | 3 | 2010 | 324 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2002 | 119 | 0.050 |
Why?
|
| Medicine | 1 | 2002 | 52 | 0.050 |
Why?
|
| Specialization | 1 | 2002 | 66 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 322 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2003 | 220 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2002 | 312 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2003 | 362 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2006 | 445 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2013 | 145 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2002 | 102 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2002 | 246 | 0.050 |
Why?
|
| Lipids | 1 | 2003 | 298 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2003 | 546 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2002 | 157 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 1083 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1447 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2002 | 281 | 0.040 |
Why?
|
| DNA | 1 | 2002 | 597 | 0.040 |
Why?
|
| RNA | 2 | 2010 | 171 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2003 | 493 | 0.040 |
Why?
|
| Aged | 4 | 2012 | 14862 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 37 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2018 | 85 | 0.040 |
Why?
|
| Lipid Metabolism | 2 | 2013 | 186 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 800 | 0.040 |
Why?
|
| Mutation | 1 | 2002 | 1213 | 0.040 |
Why?
|
| Calcimycin | 2 | 2007 | 32 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2012 | 7029 | 0.030 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 2 | 2007 | 10 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2018 | 326 | 0.030 |
Why?
|
| Pregnancy | 3 | 2007 | 2334 | 0.030 |
Why?
|
| Adult | 3 | 2012 | 21403 | 0.030 |
Why?
|
| Phospholipases A2 | 1 | 2013 | 32 | 0.030 |
Why?
|
| Phenylbutyrates | 1 | 2013 | 7 | 0.030 |
Why?
|
| Naphthalenes | 1 | 2013 | 47 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 78 | 0.030 |
Why?
|
| Financing, Government | 1 | 2012 | 16 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2012 | 58 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2013 | 175 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 160 | 0.030 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2011 | 8 | 0.020 |
Why?
|
| Ileum | 1 | 1991 | 28 | 0.020 |
Why?
|
| Jejunum | 1 | 1991 | 26 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1991 | 71 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 160 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 349 | 0.020 |
Why?
|
| Benchmarking | 1 | 2011 | 91 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1991 | 114 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2012 | 178 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 306 | 0.020 |
Why?
|
| Gastrulation | 1 | 2010 | 4 | 0.020 |
Why?
|
| Embryo, Nonmammalian | 1 | 2010 | 64 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 786 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 948 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 627 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2011 | 346 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 425 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 1753 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 53 | 0.020 |
Why?
|
| Ovulation | 1 | 2007 | 10 | 0.020 |
Why?
|
| Decidua | 1 | 2007 | 8 | 0.020 |
Why?
|
| Embryo Implantation | 1 | 2007 | 17 | 0.020 |
Why?
|
| Fertilization | 1 | 2007 | 10 | 0.020 |
Why?
|
| Trophoblasts | 1 | 2007 | 29 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2007 | 22 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 60 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2007 | 86 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2008 | 4848 | 0.020 |
Why?
|
| Dipeptides | 1 | 2007 | 89 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 47 | 0.020 |
Why?
|
| Placenta | 1 | 2007 | 101 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 581 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 284 | 0.020 |
Why?
|
| Middle Aged | 3 | 2012 | 21147 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 157 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 175 | 0.020 |
Why?
|
| Stem Cells | 1 | 2007 | 248 | 0.020 |
Why?
|
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2005 | 11 | 0.020 |
Why?
|
| Hydroxylamine | 1 | 2005 | 9 | 0.020 |
Why?
|
| Cyclic N-Oxides | 1 | 2005 | 17 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2005 | 28 | 0.020 |
Why?
|
| F2-Isoprostanes | 1 | 2005 | 14 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 36 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2005 | 47 | 0.020 |
Why?
|
| Glutathione | 1 | 2007 | 343 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 73 | 0.020 |
Why?
|
| Nitrites | 1 | 2005 | 53 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2005 | 55 | 0.020 |
Why?
|
| Nitrobenzenes | 1 | 2005 | 13 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 94 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2005 | 191 | 0.020 |
Why?
|
| Denmark | 1 | 2004 | 24 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3259 | 0.020 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2004 | 9 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 201 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2004 | 11 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2005 | 234 | 0.020 |
Why?
|
| Embryo Transfer | 1 | 2004 | 18 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2004 | 67 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2005 | 181 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 951 | 0.020 |
Why?
|
| Reoviridae Infections | 1 | 2004 | 10 | 0.020 |
Why?
|
| Metallothionein | 1 | 2004 | 20 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2005 | 217 | 0.020 |
Why?
|
| S Phase | 1 | 2004 | 38 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 331 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2005 | 155 | 0.010 |
Why?
|
| Culture Media | 1 | 2004 | 155 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2004 | 161 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2004 | 210 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2004 | 130 | 0.010 |
Why?
|
| Fibrinolysin | 1 | 2003 | 33 | 0.010 |
Why?
|
| Lung | 1 | 2008 | 849 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2005 | 455 | 0.010 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2003 | 26 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2003 | 100 | 0.010 |
Why?
|
| Linoleic Acids | 1 | 2003 | 12 | 0.010 |
Why?
|
| Antioxidants | 1 | 2005 | 304 | 0.010 |
Why?
|
| Atmospheric Pressure | 1 | 2003 | 8 | 0.010 |
Why?
|
| Peroxidases | 1 | 2002 | 28 | 0.010 |
Why?
|
| Adenomatous Polyps | 1 | 2002 | 18 | 0.010 |
Why?
|
| Hormones | 1 | 2002 | 42 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 626 | 0.010 |
Why?
|
| Uterus | 1 | 2002 | 77 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2002 | 41 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2003 | 126 | 0.010 |
Why?
|
| Progesterone | 1 | 2002 | 115 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2004 | 622 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 289 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2003 | 397 | 0.010 |
Why?
|
| Estrogens | 1 | 2002 | 173 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 780 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 718 | 0.010 |
Why?
|
| Insulin | 1 | 2004 | 619 | 0.010 |
Why?
|
| Oxygen | 1 | 2002 | 386 | 0.010 |
Why?
|
| Research Design | 1 | 2004 | 729 | 0.010 |
Why?
|
| Quality of Life | 1 | 2007 | 1515 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 1118 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 931 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2004 | 7277 | 0.010 |
Why?
|